Former Medtronic CEO Bill Hawkins Joins Ketryx Board to Drive AI Compliance in Life Sciences

William A. Hawkins, former Chairman and CEO of Medtronic, joins Ketryx's Board of Directors and participates in Series B financing, signaling industry support for Ketryx's agentic continuous compliance platform that aims to accelerate product development in safety-critical industries.

Chicago Metrowire Staff
Technology
Former Medtronic CEO Bill Hawkins Joins Ketryx Board to Drive AI Compliance in Life Sciences

Ketryx, the agentic continuous compliance platform for safety-critical product development, announced today that William A. Hawkins, former Chairman and CEO of Medtronic, has joined its Board of Directors. Hawkins also participated in the company’s Series B financing, though the terms were not disclosed.

Hawkins, who led Medtronic from 2007 to 2011 and served as chairman until 2014, brings decades of experience in the medical device industry. His tenure at Medtronic saw significant expansion and innovation in cardiovascular, diabetes, and neurological devices. The appointment underscores Ketryx’s ambition to solve what it calls the “AI bottleneck” in life sciences, where regulatory compliance often slows down the adoption of artificial intelligence tools.

Ketryx helps companies in safety-critical industries, including medical devices, pharmaceuticals, and robotics, accelerate product development by automatically generating compliant documentation, maintaining continuous traceability, and enabling safe and verifiable AI at scale in the tools teams already use. The platform overlays existing tools to automate documentation, create traceability, and accelerate release cycles without disrupting existing workflows. According to Ketryx, its AI agents reduce manual work by up to 90 percent and help teams identify and close compliance gaps, improving both speed and quality across the product lifecycle.

The company is trusted by four of the world's top five medical device manufacturers, indicating strong market traction. With regulatory bodies like the FDA increasingly scrutinizing software and AI in medical devices, Ketryx’s platform addresses a critical need for automating compliance while maintaining safety and efficacy standards.

Hawkins’ involvement is likely to bolster Ketryx’s credibility and strategic direction. His experience navigating complex regulatory environments and scaling global operations could prove invaluable as the company expands its footprint. The participation in Series B financing also signals confidence in Ketryx’s growth trajectory.

Ketryx transforms the product lifecycle of life sciences teams to deliver safer products, faster. For more information, visit www.ketryx.com.

Blockchain Registration

QR Code for Blockchain Registration